All In Biotech

Drug Trial Radar · NCT04779242

Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia

A Phase 3b Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Moxifloxacin IV/PO for Treating Adult Subjects With Community-Acquired Bacterial Pneumonia (CABP)

Last checked: Nov 20, 2026Latest source record: Apr 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 670 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

670

Actual

Start

Feb 25, 2021

Primary completion

Mar 27, 2024

Study completion Mar 27, 2024

Sponsor

Lead sponsor
Paratek Pharmaceuticals IncIndustry
Sponsor type
Industry
First posted
Mar 3, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of omadacycline as compared to moxifloxacin in the treatment of adults with community-acquired bacterial pneumonia.

Conditions

  • Community-acquired Pneumonia
  • Bacterial Pneumonia

Interventions

  • OmadacyclineDrug

    IV for injection, oral tablets

  • MoxifloxacinDrug

    IV solution, oral tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Early Clinical Response at the Early Clinical Response (ECR) VisitTime frame: 72 to 120 hours after the first dose of test article

Locations

55 sites in 8 countries. Site status is shown where the registry gives one.

  • Site 210

    Gabrovo, Bulgaria

  • Site 213

    Lom, Bulgaria

  • Site 208

    Pernik, Bulgaria

  • Site 201

    Pleven, Bulgaria

  • Site 206

    Rousse, Bulgaria

  • Site 207

    Sliven, Bulgaria

  • Site 202

    Sofia, Bulgaria

  • Site 204

    Sofia, Bulgaria

  • Site 205

    Sofia, Bulgaria

  • Site 209

    Sofia, Bulgaria

  • Site 212

    Vidin, Bulgaria

  • Site 211

    Vratsa, Bulgaria

  • Site 302

    Split, Croatia

  • Site 301

    Zagreb, Croatia

  • Site 303

    Zagreb, Croatia

  • Site 304

    Zagreb, Croatia

  • Site 401

    Tbilisi, Georgia

  • Site 402

    Tbilisi, Georgia

  • Site 403

    Tbilisi, Georgia

  • Site 404

    Tbilisi, Georgia

  • Site 405

    Tbilisi, Georgia

  • Site 406

    Tbilisi, Georgia

  • Site 407

    Tbilisi, Georgia

  • Site 802

    Balassagyarmat, Hungary

  • Site 801

    Budapest, Hungary

  • Site 803

    Debrecen, Hungary

  • Site 804

    Kistarcsa, Hungary

  • Site 805

    Törökbálint, Hungary

  • Site 901

    Chrzanów, Poland

  • Site 904

    Krakow, Poland

  • Site 903

    Łęczna, Poland

  • Site 902

    Oświęcim, Poland

  • Site 506

    Moscow, Russia

  • Site 510

    Moscow, Russia

  • Site 507

    Saint Petersburg, Russia

  • Site 508

    Saint Petersburg, Russia

  • Site 509

    Saint Petersburg, Russia

  • Site 703

    Belgrade, Serbia

  • Site 704

    Belgrade, Serbia

  • Site 705

    Belgrade, Serbia

Showing 40 of 55 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.